Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M. Cancello G, et al. Breast Cancer Res Treat. 2011 Jun;127(3):713-20. doi: 10.1007/s10549-011-1465-7. Epub 2011 Mar 31. Breast Cancer Res Treat. 2011. PMID: 21452022
Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure.
Montagna E, Viale G, Rotmensz N, Maisonneuve P, Galimberti V, Luini A, Intra M, Veronesi P, Mazzarol G, Pruneri G, Renne G, Torrisi R, Cardillo A, Cancello G, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: cancello g. Breast Cancer Res Treat. 2009 Nov;118(2):385-94. doi: 10.1007/s10549-009-0446-6. Epub 2009 Jun 27. Breast Cancer Res Treat. 2009. PMID: 19562480 Free article.
Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.
Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M. Cancello G, et al. Ann Oncol. 2010 Oct;21(10):1974-1981. doi: 10.1093/annonc/mdq072. Epub 2010 Mar 23. Ann Oncol. 2010. PMID: 20332136 Free article.
Breast cancer subtypes and outcome after local and regional relapse.
Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: cancello g. Ann Oncol. 2012 Feb;23(2):324-31. doi: 10.1093/annonc/mdr129. Epub 2011 Apr 27. Ann Oncol. 2012. PMID: 21525402 Free article.
Outcome of special types of luminal breast cancer.
Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, Intra M, Montagna E, Cancello G, Cardillo A, Mazza M, Perri G, Iorfida M, Pruneri G, Goldhirsch A, Viale G. Colleoni M, et al. Among authors: cancello g. Ann Oncol. 2012 Jun;23(6):1428-36. doi: 10.1093/annonc/mdr461. Epub 2011 Oct 29. Ann Oncol. 2012. PMID: 22039080 Free article.
Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.
Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, Balduzzi A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Casadio C, Sangalli C, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: cancello g. Ann Oncol. 2015 Feb;26(2):307-13. doi: 10.1093/annonc/mdu528. Epub 2014 Nov 19. Ann Oncol. 2015. PMID: 25411418 Free article.
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: cancello g. Breast Cancer Res Treat. 2010 Dec;124(3):689-99. doi: 10.1007/s10549-010-1027-4. Epub 2010 Jul 13. Breast Cancer Res Treat. 2010. PMID: 20625816
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
Torrisi R, Montagna E, Scarano E, Dellapasqua S, Cancello G, Iorfida M, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Among authors: cancello g. Breast. 2011 Feb;20(1):34-8. doi: 10.1016/j.breast.2010.06.005. Epub 2010 Jul 16. Breast. 2011. PMID: 20638282 Free article.
Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.
Torrisi R, Cardillo A, Cancello G, Dellapasqua S, Balduzzi A, Ghisini R, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Among authors: cancello g. Clin Breast Cancer. 2010 Dec 1;10(6):483-8. doi: 10.3816/CBC.2010.n.064. Clin Breast Cancer. 2010. PMID: 21147693 Clinical Trial.
45 results